6 questions for Tony Coles as he tackles protein misfolding diseases

December 15, 2014 10:43 PM

10 0

6 questions for Tony Coles as he tackles protein misfolding diseases

Over the past five years or so, there probably was no company that better represented the promise of mid-sized biotech companies than Onyx Pharmaceuticals. So when Onyx was sold in fall 2013 to Amgen Inc., there was a collective holding of breath about the future of the 800-employee company's future in South San Francisco, and what it meant for CEO Tony Coles.

Coles was more than the leader of the company. After arriving in March 2008, he became the face of the Bay Area's biotech industry and a leader in trying to make clinical trials of experimental drugs more efficient.

Read more

To category page

Loading...